Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor

Detalles Bibliográficos
Autores principales: Majagi, Shreya, Mangat, Sharan, Chu, Xiang-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294732/
https://www.ncbi.nlm.nih.gov/pubmed/35865964
http://dx.doi.org/10.3389/fphar.2022.938748
_version_ 1784749906495275008
author Majagi, Shreya
Mangat, Sharan
Chu, Xiang-Ping
author_facet Majagi, Shreya
Mangat, Sharan
Chu, Xiang-Ping
author_sort Majagi, Shreya
collection PubMed
description
format Online
Article
Text
id pubmed-9294732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92947322022-07-20 Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor Majagi, Shreya Mangat, Sharan Chu, Xiang-Ping Front Pharmacol Pharmacology Frontiers Media S.A. 2022-07-05 /pmc/articles/PMC9294732/ /pubmed/35865964 http://dx.doi.org/10.3389/fphar.2022.938748 Text en Copyright © 2022 Majagi, Mangat and Chu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Majagi, Shreya
Mangat, Sharan
Chu, Xiang-Ping
Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor
title Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor
title_full Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor
title_fullStr Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor
title_full_unstemmed Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor
title_short Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor
title_sort commentary: pharmacological validation of asic1a as a druggable target for neuroprotection in cerebral ischemia using an intravenously available small molecule inhibitor
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294732/
https://www.ncbi.nlm.nih.gov/pubmed/35865964
http://dx.doi.org/10.3389/fphar.2022.938748
work_keys_str_mv AT majagishreya commentarypharmacologicalvalidationofasic1aasadruggabletargetforneuroprotectionincerebralischemiausinganintravenouslyavailablesmallmoleculeinhibitor
AT mangatsharan commentarypharmacologicalvalidationofasic1aasadruggabletargetforneuroprotectionincerebralischemiausinganintravenouslyavailablesmallmoleculeinhibitor
AT chuxiangping commentarypharmacologicalvalidationofasic1aasadruggabletargetforneuroprotectionincerebralischemiausinganintravenouslyavailablesmallmoleculeinhibitor

Ejemplares similares